EDSA

Edesa Biotech, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.01
52-Week Range: $0.72 – $20.32
Market Cap: $52.15M
P/E (TTM): —
EPS (TTM): -1.72
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 94.15
PEG Ratio: —
Return on Equity: -122.93%
Return on Assets: -66.43%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 2.76
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-4.01M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $35.29M

EDSA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$13.34M	$4.79M	$2.88M	$3.67M
Selling, General & Admin	$5.04M	$4.43M	$4.13M	$4.24M
Operating Expenses	$17.59M	$8.64M	$6.32M	$7.13M
Operating Income	-$17.59M	-$8.64M	-$6.32M	-$7.13M
EBITDA	-$17.47M	-$8.46M	-$6.13M	-$7.01M
Pretax Income	-$17.55M	-$8.37M	-$6.17M	-$7.18M
Income Tax	$800.00	$800.00	$800.00	$800.00
Net Income	-$17.55M	-$8.37M	-$6.17M	-$7.19M
Diluted EPS	-7.35	-2.93	-1.93	-1.27
Diluted Shares	2.38M	2.86M	3.20M	5.68M

EDSA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$7.09M	$5.36M	$1.04M	$10.79M
Receivables	$1.26M	$626.54K	$270.91K	$642.87K
Current Assets	$9.09M	$6.44M	$1.68M	$11.51M
Total Assets	$11.58M	$8.89M	$3.81M	$13.53M
Current Liabilities	$2.14M	$1.82M	$1.83M	$1.08M
Total Debt	$18.98K	$94.49K	$19.87K	$0.00
Total Liabilities	$2.18M	$1.84M	$1.83M	$1.08M
Retained Earnings	-$44.04M	-$52.42M	-$58.59M	-$65.91M
Shareholders' Equity	$9.39M	$7.05M	$1.98M	$12.45M
Working Capital	$6.95M	$4.61M	-$157.21K	$10.43M

EDSA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.28M	-$6.64M	-$4.89M	-$7.32M
Capital Expenditure	-$5.66K	—	—	—
Free Cash Flow	-$12.28M	-$6.64M	-$4.89M	-$7.32M
Depreciation & Amortisation	$118.19K	$183.47K	$186.05K	$119.27K
Stock-Based Compensation	$2.26M	$1.25M	$537.49K	$729.64K
Investing Cash Flow	-$5.66K	$0.00	—	—
Financing Cash Flow	$11.63M	$4.83M	$592.03K	$17.03M
Net Change in Cash	-$655.33K	-$1.81M	-$4.30M	$9.71M

EDSA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$484.31K	$939.07K	$1.23M	$1.12M	$2.77M	$3.96M
Selling, General & Admin	$1.15M	$964.68K	$1.24M	$1.22M	$1.53M	$1.56M
Operating Expenses	$1.59M	$1.72M	$2.22M	$2.24M	$4.23M	$5.41M
Operating Income	-$1.59M	-$1.72M	-$2.22M	-$2.24M	-$4.23M	-$5.41M
EBITDA	-$1.56M	-$1.69M	-$2.20M	-$2.21M	-$4.20M	-$5.39M
Pretax Income	-$1.59M	-$1.75M	-$2.23M	-$2.25M	-$4.22M	-$5.41M
Income Tax	$800.00	$0.00	$0.00	—	$800.00	$0.00
Net Income	-$1.59M	-$1.75M	-$2.23M	-$2.25M	-$4.22M	-$5.41M
Diluted EPS	-0.30	-0.25	—	-0.28	-0.49	-0.60
Diluted Shares	5.31M	7.02M	—	7.97M	8.54M	9.01M

EDSA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$13.90M	$12.36M	$10.79M	$12.05M	$10.00M	$10.33M
Receivables	$382.44K	$286.74K	$642.87K	$431.32K	$216.47K	$228.05K
Current Assets	$14.39M	$12.76M	$11.51M	$12.72M	$10.42M	$10.78M
Total Assets	$16.45M	$14.80M	$13.53M	$14.71M	$12.38M	$12.72M
Current Liabilities	$914.70K	$672.67K	$1.08M	$756.16K	$2.19M	$3.91M
Total Debt	$0.00	$0.00	$0.00	—	—	—
Total Liabilities	$914.70K	$672.67K	$1.08M	$756.16K	$2.19M	$3.91M
Retained Earnings	-$61.86M	-$63.65M	-$65.91M	-$68.20M	-$72.45M	-$77.90M
Shareholders' Equity	$15.54M	$14.13M	$12.45M	$13.95M	$10.20M	$8.81M
Working Capital	$13.47M	$12.09M	$10.43M	$11.96M	$8.23M	$6.87M

EDSA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$2.38M	-$1.70M	-$1.72M	-$2.09M	-$2.02M	-$3.08M
Free Cash Flow	-$2.38M	-$1.70M	-$1.72M	-$2.09M	-$2.02M	-$3.08M
Depreciation & Amortisation	$24.51K	$25.79K	$25.87K	$25.46K	$25.87K	$25.64K
Stock-Based Compensation	$66.65K	$177.38K	$404.43K	$399.86K	$484.85K	$547.46K
Financing Cash Flow	$14.77M	$0.00	$186.48K	$3.36M	-$8.98K	$3.45M
Net Change in Cash	$12.39M	-$1.70M	-$1.53M	$1.27M	-$2.03M	$364.26K

Market Snapshot

About

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for inflammatory and immune-related diseases. The company's lead product candidate, EB05, is being investigated for acute respiratory distress syndrome and other conditions involving excessive inflammation. Edesa is also developing dermatology treatments and other antibody-based therapies targeting unmet medical needs. Headquartered in Ontario, Canada, the company focuses on repurposing and advancing novel applications of antibody platforms through clinical development.